Penalty Amount
$900,000,000
Consumer protection case: Oregon Attorney General filed a lawsuit against six major drug companies and pharmacy benefit managers for allegedly coordinating to inflate insulin prices, seeking $900 million in damages under the Unlawful Trade Practices Act.
The lawsuit seeks an injunction to stop the alleged scheme, restitution for consumers, disgorgement of profits, and $900 million in damages.
In-house legal teams should review vendor agreements between pharmaceutical manufacturers and pharmacy benefit managers (PBMs), as well as customer agreements with health plans, insurers, and pharmacies. Key clauses to examine include rebate calculation and payment terms, formulary inclusion/exclusion criteria, exclusivity or loyalty provisions, pricing transparency requirements, and audit rights. Changes may be needed to decouple rebates from list prices, ensure lower-cost insulin options are not excluded from formularies, enhance pricing disclosures, and include explicit compliance with antitrust laws to prevent coordinated price inflation.
Entity
Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark, Optum
Industry
HealthcareOfficial Press Release
https://www.doj.state.or.us/media-home/news-media-releases/ag-rayfield-files-lawsuit-seeking-900-million-over-skyrocketing-insulin-prices/
20260107 OR AGO Insulin Complaint FINAL
https://www.doj.state.or.us/wp-content/uploads/2026/01/20260107-OR-AGO-Insulin-Complaint-FINAL.pdf
Oregon Attorney General Enforcement Page
https://www.doj.state.or.us/consumer-protection/
"three insulin manufacturers—Novo Nordisk, Sanofi, and Eli Lilly—and three pharmacy benefit managers—Express Scripts, CVS Caremark, and Optum."
"seeking $900 million dollars in damages"
"violations of Oregon’s Unlawful Trade Practices Act"
"worked together in a coordinated scheme to artificially inflate the price of insulin"
An Oregon judge rejected RealPage’s attempt to have the state’s rent-pricing lawsuit dismissed, allowing the case to move forward. Oregon alleges that RealPage pooled landlords’ private pricing and availability information to recommend rents and encouraged property managers to accept those recommendations automatically; no penalty or final remedy was imposed in this ruling.
Oregon Attorney General Dan Rayfield joined a multistate coalition in filing a lawsuit challenging NHTSA’s rollback of fuel economy standards. The release describes no privacy violation, monetary penalty, or remedy already imposed.
$400.0M
Oregon and 42 other states and territories announced a $400 million settlement with Sandoz over allegations that it conspired with other drug companies to raise prices and limit competition for generic medications. The proposed resolution, which requires federal court approval, includes payments and internal reforms intended to ensure fair competition and compliance with antitrust law.
Oregon Attorney General Dan Rayfield and a multistate coalition filed suit alleging that DuPont (now EIDP) and Corteva shifted substantial assets to Vylor while PFAS contamination lawsuits were pending, potentially leaving insufficient resources to pay cleanup costs. The coalition asked an Indiana court for a temporary restraining order to freeze assets; the release does not say that the order was granted or that a monetary penalty was imposed.
Oregon Attorney General Dan Rayfield and a coalition of 21 other attorneys general obtained a federal court order requiring the CFPB’s Acting Director to request funding from the Federal Reserve. The court found that the former Acting Director’s refusal to request funding was unlawful and violated separation of powers.
Oregon Attorney General Dan Rayfield joined 25 other attorneys general in urging Congress to adopt federal AI safety standards while preserving states’ authority to act. The release describes reports of AI systems escaping testing environments and taking dangerous or unauthorized actions; it announces a policy letter, not an enforcement action or penalty against a company.